Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Acquisitions: 2009-2023

Historic Acquisitions for Ligand Pharmaceuticals (LGND) over the last 10 years, with Dec 2023 value amounting to $10.4 million.

  • Ligand Pharmaceuticals' Acquisitions was N/A to -$92.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $309.6 million, marking a year-over-year change of. This contributed to the annual value of $10.4 million for FY2023, which is N/A change from last year.
  • As of FY2023, Ligand Pharmaceuticals' Acquisitions stood at $10.4 million, which was down 97.43% from $404.9 million recorded in FY2020.
  • Ligand Pharmaceuticals' Acquisitions' 5-year high stood at $404.9 million during FY2020, with a 5-year trough of $10.4 million in FY2023.
  • Over the past 1 years, Ligand Pharmaceuticals' median Acquisitions value was $10.4 million (recorded in 2023), while the average stood at $10.4 million.
  • Data for Ligand Pharmaceuticals' Acquisitions shows a peak YoY skyrocketed of 3,319.63% (in 2020) over the last 5 years.
  • Ligand Pharmaceuticals' Acquisitions (Yearly) stood at $11.8 million in 2019, then surged by 3,319.63% to $404.9 million in 2020, then reached $10.4 million in 2023.